Comparative genomic hybridisation has been used to map copy number changes in nine cases of ductal carcinoma in situ of the breast obtained from waxembedded archive material. A wide variety of abnormalities were detected including gain of regions of 1q, 17q, 19q, 20p and 20q and loss on 13q, 14q, 17p, 16q and 22q. Ampli®cation of areas on 10p, 8q and 20q were also observed. Chromosomal alterations were more frequent in higher grade DCIS and closely resemble those previously detected in invasive breast cancer using the same technique. These data provide strong molecular support for the view that DCIS is a precursor lesion of invasive breast carcinoma.
Introduction
Breast cancer is the most common malignancy aecting women in the developed world, accounting for over 16 000 deaths per year in the UK (Cancer Research Campaign Factsheet 6, 1991) . However, it is a complex disease and it is dicult to pinpoint speci®c events which may be involved with disease initiation or progression. Ductal carcinoma in situ (DCIS) of the breast is characterised by a proliferation of duct epithelial cells with cytological features of malignancy which have not in®ltrated the basement membrane. There is some evidence that DCIS may be a precursor lesion for malignant breast cancer (Betsill et al., 1978; Page et al., 1982) , since it is often seen at sites adjacent to invasive breast cancer and invasive recurrence after treatment for DCIS often occurs at the site of the original biospy. This suggests that patients exhibiting DCIS are at increased risk of progressing to develop invasive carcinoma (Page et al., 1982) . However, evidence is mainly derived from epidemiological data as, until recently, it was a relatively rarely diagnosed tumour. Before the introduction of mammography, DCIS accounted for less than 5% of breast tumours (Rosner et al., 1980) but the use of routine mammography screening has increased greatly the detection of DCIS in asymptomatic patients providing a patient population to study. However these lesions are treated by mastectomy or wide local excision due to the risk of developing later invasive carcinoma, and as a result little is known about progression of the lesion.
Analysis of genetic changes in premalignant or malignant lesions can be approached in several ways. The chromosome complement can be studied for alterations to particular chromosomes and studies in DCIS show that they exhibit abnormal karyotypes (Nielsen et al., 1989) . However cytogenetic studies suer from the need to obtain enough cells in division for analysis. An alternative method is to examine the genes or chromosomal regions which may be implicated in DCIS, seeking to identify changes in these lesions. Polymerase chain reaction (PCR) may be used to amplify DNA from tumour cells microdissected directly from ®xed, wax-embedded samples. Using this approach, microsatellite markers from several chromosomal locations have been used to de®ne regions of allelic imbalance in DCIS and to examine speci®c genes for sequence mutations (Lui et al., 1992; Radford et al., 1993; O'Malley et al., 1994; Munn et al., 1995 Munn et al., , 1996a Stratton et al., 1995) . However, these studies are biased towards regions of the genome previously implicated as important to tumour initiation or progression. A more informative approach would be to scan the entire genome at once for alterations. The discovery of similar genetic alterations in DCIS and invasive breast carcinoma would provide stronger evidence that DCIS is a direct precursor lesion of invasive cancer.
Comparative genomic hybridisation (CGH) is a relatively new technique aimed at detecting ampli®ed and/or deleted regions of DNA in tumours (Kallioniemi et al., 1992) . It does not rely on the analysis of tumour karyotypes as tumour DNA and normal DNA are labelled, mixed in equal proportion and hybridised to normal metaphase chromosomes. The hybridisation pattern of tumour and normal DNA along each chromosome is then analysed by examination of the ratio of¯uorochrome labels. The technique has been applied to several sources of tumour DNA including cells microdissected from ®xed paran-embedded tissue sections (Speicher et al., 1993 Wiltshire et al., 1995; James and Varley, 1996) . This oers the advantage of access to archival material and also results in an increase in the purity of test samples as contamination with normal cells is low. It is therefore an ideal method for chromosomal analysis of ductal carcinoma in situ of the breast.
We have carried out a detailed analysis by CGH of nine cases of DCIS for genomic alterations. By comparing the range of genetic lesions seen with those known to occur in invasive breast tumours, we are addressing the question of the possible pre-invasive status of DCIS.
Results
This study reports CGH results from nine cases of ductal carcinoma in situ of the breast. In all cases material for analysis was obtained from formalin-®xed, wax-embedded sections by microdissection and DNA extraction. Details of the tumours are given in Table 1 .
Initially the control slide hybridised with equal quantities of rhodamine and FITC-labelled normal control DNA was examined to determine the quality of data produced and to set the¯uorescence ratio thresholds for later analysis of the tumour material. In theory, if the hybridisation of the two labelled DNAs is perfect, the ratio of¯uorochromes along each chromosome will be uniform and therefore equal exactly 1.0. Although some small¯uctuations in hybridisation eciency are inevitable in practice, an even hybridisation across each chromosome was achieved, and this was re¯ected by a ratio pro®le averaged from at least ®ve homologues which was close to 1.0 for each chromosome (data not shown but made available to referees). Based on these data, an FITC : rhodamine ratio value of greater than 1.25 was chosen to identify DNA copy number increases and of less than 0.75 to identify copy number decreases in the tumour. These ratios are conservative, but take into account the upper and lower limits of¯uctuation from the ratio of 1.0 at any autosomal chromosome location in the control experiments.
After assessment of the control slide and determination of the degenerate oligonucleotide primed PCR (DOP-PCR) probe speci®city, analysis of the DCIS DNA was performed. Gain or loss were deduced by determining¯uctuations outside the limits set in the control experiments of 1.25 (for gain) or 0.75 (for loss). We further characterised gain as a low level gain where the ratio increased above 1.25 up to 2.0 and ampli®cation where the ratio increased over 2.0. Hybridisation of the DOP-PCR probes to the Y chromosome was consistently limited to the pseudoautosomal region which has homology to sequences on chromosome X. Poor hybridisation across the rest of the chromosome was seen, this was expected since both the test and control probes were prepared from female tissue and indicated that the probes prepared by DOP-PCR were highly speci®c (see Figure 2) . Figure 1 Mean¯uorescence ratio pro®les (red trace) for chromosome 10 generated by comparative genomic hybridisation analysis of a case of ductal carcinoma in situ of the breast (case 6216). (a) Initial experiment suggests ampli®cation of a region on the short arm of chromosome 10 (identi®ed as 10p12.3-15). (b) Alteration of 10p was con®rmed after re-dissection of the tumour cells from a sequential section and re-ampli®cation of the tumour DNA. The¯uorescence ratio in this 2nd experiment does not exceed 2.0 and would therefore be designated as`gain' rather thaǹ ampli®cation'. The number of homologues used to calculate the mean pro®les (n) is given beside the graph. A mean¯uorescence ratio of 1.0 is shown by the black horizontal line
The validity of the CGH data obtained in this study was con®rmed using case 6216. Initial CGH results indicated one region of DNA gain at 9p23-24 and a second, higher level ampli®cation of chromosome region 10p12.3-15. After re-dissection of the tumour cells from another section, a second CGH experiment was performed. This identi®ed the same regions of alteration on chromosomes 9p and 10p which con®rm the reproducibility of the technique, although the fluorescence ratio on 10p was not above 2.0 and could not therefore be designated as an ampli®cation in this experiment. This variability may be due to dierences in the number of tumour cells sampled between the sections which contain the 10p alteration or may re¯ect altered hybridisation eciency between dierent metaphase chromosome preparations. The chromosome 10 ideograms from each experiment are shown in Figure 1 .
Gain and/or deletion of whole chromosomes, chromosome arms or sub-chromosomal regions was detected by CGH in all but one case (no. 5082) studied. Of the eight remaining cases, six had a small number (53) of aberrations while two had a larger number of changes. A summary of the CGH results obtained for each case is given in Table 1 . An example of the CGH analysis for case 884 is shown in Figure 2 .
Regions of increased copy number were mapped to 1q21-23, 1q31.3-32 and 17q21; no regions of autosome loss were identi®ed. A summary of the CGH results obtained for all of the cases where copy number changes were detected is shown in Figure 3 .
Discussion
This study reports the analysis by CGH of gain and/ or loss of genomic regions in ductal carcinoma in situ of the breast. The importance of DCIS in the progression pathway of breast cancers is unclear at present. Studies on other tumours, for example colorectal cancer, have shown that the accumulation of speci®c genetic alterations is associated with progression of the disease (Fearon and Vogelstein, 1990) . However there is no such clear cut pathway to de®ne breast cancer. One model (Frykberg and Bland, 1993) , suggests that breast cancer may evolve from normal breast epithelial cells through proliferative disorders such as ductal or lobular hyperplasia to carcinoma in situ. Eventually the disease progresses to invasive carcinoma as the cells invade the surrounding tissue. The position of DCIS in the progression The number of homologues (n) used to calculate the¯uorescence ratio is given below each graph. Note the poor hybridisation of the probes to chromosome Y indicating the speci®city of the degenerate oligonucleotide primed PCR probes prepared from female material. The mean ratio pro®le graphs generated from at least ®ve homologues from ®ve separate metaphases show gain of 1q21-23, 1q31.32 and 17q21. Images of representative chromosomes 1, 12, 15 and 17 are showed next to the respective ideograms pathway makes it an important tumour to study. With the introduction of mammography screening DCIS now accounts for up to 30% of breast lesions detected in a screened population (Frykberg and Bland, 1993) . In addition, the possibility of preparing DNA from paran-embedded material has allowed access to pathology archive material. It is now possible to identify and analyse DNA aberrations in DCIS tumours and to compare these to those already reported in invasive breast tumours. The CGH technique lends itself to this task as it is a`global' approach, analysing across the whole genome in a single experiment and is not biased in favour of any particular chromosomal region.
Several groups have recently reported the analysis of primary invasive breast tumours by CGH Muleris et al., 1994; Isola et al., 1994; . Together, their results con®rm a complex picture of gain and loss across many chromosomes. The most common regions of gain highlighted in these studies include regions of 1q, 3q, 6p, 8q, 11q, 12q, 17q and 20q. Only two of the four reports identi®ed any chromosomal losses, the most common of which were of 3p, 6q, 8p, 12q, 14q, 15q, 16q and 20q. The report by Ried and coworkers made a further interesting observation in 13 ®broadenomas studied by CGH . They could ®nd no evidence of genomic imbalance in these benign lesions and conclude that they are therefore not likely to be pre-cancerous.
The DCIS cases studied here revealed a number of chromosomal gains and losses which are summarised in Table 1 and Figure 3 . Both gain and loss of chromosomal material was widely distributed among a number of chromosomes and consistent changes were not observed in a large proportion of the cases studied. In general the number of aberrations observed in DCIS was less (4.2 per case) than those observed by Ried for aneuploid invasive carcinoma (6.8 per case), although perhaps surprisingly more than those observed for diploid invasive carcinoma (2.4 per cases, Ried et al., 1995) . However the ®gure for DCIS is biased by cases 7086 and 6050 (18 and 10 aberrations respectively) and the average number of aberrations per case is reduced to 1.4 if these two tumours are excluded from the analysis. Variation in the frequency of alterations observed here compared with that seen by others may be due to the relatively small number of cases examined in this preliminary study or may simply re¯ect dierences in the exact CGH methodology or interpretation between laboratories.
Perhaps more relevant than the number of abnormalities observed is their location. The most common regions of gain, identi®ed in 2/9 cases, were on 1q, 17q, 19q, 20p and 20q. Common regions of loss on 13q, 14q and 16q were also identi®ed in more than one case. The remaining aberrations were only observed in a single case. The majority of abnormalities detected in these cases of DCIS correspond to areas previously reported by others analysing invasive breast carcinoma by CGH. For example, the overrepresentation of regions on chromosome 1q observed in cases 884 and 1166 has also been reported in each of the CGH analyses of invasive breast cancer Muleris et al., 1994; Isola et al., 1994; Ried et al., 1995) . Indeed, abnormalities of this chromosome are also consistently observed in other cancers (Teyssier, 1989) . Karyotyping of breast cancer cell lines has shown that the most frequent aberrations (Dutrillaux et al., 1990 (Dutrillaux et al., , 1991 . Loss of 16q was the sole abnormality detected by CGH in DCIS case 3325.
In addition to abnormalities reported on chromosome 1, high level ampli®cation of regions on 8q (case 6050), 20q (case 7806 and 6050) and 10p (case 6216) have been identi®ed in the present study. Again these are all regions where aberrations have previously been observed in invasive breast tumours by CGH. Indeed the increased copy number at 20q13 emerged as one of the most common genetic aberrations in breast cancer only after CGH analysis . The critical region has since been de®ned as a 1.5 Mb DNA segment at 20q13.2 which is thought to harbour a novel oncogene involved in breast cancer. The c-myc oncogene is located on chromosome band 8q24 and it is likely that this is the target of the ampli®cation site identi®ed in case 6050. The region of ampli®cation located on chromosome 10q12.3-15 in case 6216 is concordant with the report of Ried and co-workers who also observed ampli®cation at this site in a single case of aneuploid breast carcinoma . Although no oncogenes known to be associated with breast cancer have been reported to map here, a total of 17 genes have been localised to the region to date (Genome database version 6.0, http://gdbwww.gdb.org). These include a murine leukaemia viral bmi-1 oncogene homologue (BMI1) which may be a potential target of ampli®cation. Further studies of this region are warranted.
Regions of loss observed in the DCIS tumours characterised in the present study include 17p (case 7806), 22q (case 1880), 13q and 14q (both seen in cases 6050 and 7806) and 16q (cases 6050 and 3325). Losses at many of these regions have been detected in invasive breast tumours by CGH Ried et al., 1995) , and a number of candidate targets for loss map to these regions. The tumour suppressor gene TP53 is located at 17p13.1 and a second candidate tumour suppressor locus at 17q13.3 (Stack et al., 1995) ; NF2 maps to 22q12.2 and both RB1 and BRCA2 map to 13q. A candidate target for the loss seen on 14q has yet to be identi®ed, but LOH studies indicate that a number of candidate tumour suppressors could map to 14q (Cox et al., 1995) .
Although the number of cases of DCIS reported in the present study is limited, it is possible to draw some conclusions with regard to patterns of gain and loss seen and the nuclear grade of the tumours. In the three cases designated as low nuclear grade, one case (5082) showed no detectable aberrations, and the other two (cases 1880, 3325) showed one aberration each, both losses. In contrast, with the exception of case 1234 (Table 1 ) tumours designated as intermediate or high nuclear grade had a higher number of aberrations. Further studies are underway to address these questions. With regard to the DCIS architecture, both comedo, cribiform, micropapillary and clinging structures were identi®ed in the tumours analysed but when the microdissection was carried out, multiple ducts of all types present in any one tumour were isolated and pooled (numbers of each subtype given in Table 1) so that intraduct variation could not be analysed. There is evidence that genetic lesions are more frequent in tumours of comedo subtype, and indeed the three tumours without a comedo component show the least number of genetic alterations (cases 1880, 3325 and 5082). These tumours are, however, those with low nuclear grade, and so it is more likely that the nuclear grade of the tumour has some bearing on the number of aberrations observed.
From the analysis of DCIS tumour material reported here it is possible to draw a number of conclusions. First, it is clear that aberrations, detectable by CGH, are present in DCIS. Second, it appears that there are generally fewer aberrations seen in the DCIS tumour material than in invasive breast cancer samples previously studied by other groups. Third, the chromosomal abnormalities implicated in DCIS resemble those detected in invasive breast cancer. Finally, DCIS lesions with high nuclear grade are those in which there are a higher number of aberrations. These observations taken together strongly suggest that DCIS is a pre-invasive precursor lesion of invasive breast carcinoma. Analysis of further cases is now required to con®rm and extend these ®ndings.
Materials and methods

Patient material
Specimens from nine cases of DCIS (mean patient age=62, range 56 ± 79 years), collected between 1988 and 1994, were obtained from the Christie Hospital, Manchester, UK. All tissues were ®xed for a minimum of 24 h in buered formalin (0.4% sodium acid phosphate, 0.65% sodium phosphate) prior to wax embedding. In all cases, the histological classi®cation by nuclear grade (Bellamy et al., 1993 , NHSBSP Publication No 3, 1995 and growth pattern of the tumour was con®rmed by one of us (LM). Of the cases, ®ve were pure DCIS and did not contain an invasive component while in four cases small foci of invasion were present. Patient details and histological classi®cation are given in Table 1 .
DNA preparation
Details of the methods used to prepare and label probes from paran-embedded material and their use in CGH experiments have been given elsewhere (James and Varley, 1996) . Brie¯y, areas of tumour cells were ®rst identi®ed by examination of haematoxylin/eosin stained tissue sections. An adjacent section (5 ± 20 mm) was then dewaxed with xylene and rehydrated through an ethanol series before regions of tumour cells were microdissected using a sterile glass needle. Multiple ducts were microdissected from each section, including ducts of dierent histological subtypes, and the material was pooled prior to DNA extraction. In this way the test samples contained almost exclusively DCIS tumour cells with little contaminating normal tissue. Care was taken where necessary to avoid any areas close to, or within regions of microinvasion. DNA was extracted from the microdissected material by proteinase K/phenol extraction followed by ethanol precipitation and was resuspended in TE buer. Control DNA from a normal female human placenta was also prepared using standard methods.
DNA ampli®cation and labelling
Both the control and test DNA samples were ampli®ed separately by DOP-PCR (Telenius et al., 1992) using methods outlined in detail elsewhere (James and Varley, 1996) . Following initial ampli®cation, the test DNA products were labelled using FITC-11-dUTP (FluoroGreen, Amersham) and the control DNA products were labelled with Rhodamine-4-dUTP (FluoroRed, Amersham) incorporated during a second round of DOP-PCR. The concentration of dTTP in the dNTP mixture in the second round PCR was reduced to facilitate incorporation of the labelled nucleotide.
Metaphase chromosome preparation
Metaphase chromosome spreads were prepared from PHAstimulated lymphocytes obtained from a cytogenetically normal male (46,XY) according to methods outlined previously . Incorporation of BrdU in the culture medium allowed simultaneous DAPI banding which aided sub-chromosomal mapping. Chromosomes were denatured in 70% deionised formamide/26SSC at 808C for 4 min and dehydrated through an ice-cold ethanol series immediately prior to use.
Fluorescence in situ hybridisation
After labelling, approximately 0.5 mg of test and control DNA together with 50 mg human Cot-1 DNA (Sigma) were mixed, precipitated and resuspended in hybridisation buer (50% deionised formamide, 10% dextran sulphate in 26SSC). The probe mixture was denatured at 808C for 5 min, pre-incubated at 378C for 30 min and then hybridised under a sealed glass coverslip to denatured metaphase chromosomes for 5 days at 378C. The slides were washed to high stringency in three washes at 428C in 50% formamide/26SSC followed by three washes at 428C in 0.16SSC. The signal from the FITC-labelled test DNA was enhanced by successive incubation with mouse antiuorescein (Boehringer, 0.4 mg/ml ®nal concentration) followed by FITC-conjugated rabbit anti-mouse (Dako, 0.8 mm/ml ®nal concentration). The chromosomes were counterstained with DAPI (0.5 mg/ml) and mounted in antifade solution (Citi¯uor) under a glass coverslip.
Microscopy and image analysis
Slides were viewed using a Zeiss Axioskop Fluorescence microscope equipped with single band excitation ®lters for each¯uorochrome mounted in a computer-controlled ®lter wheel. Grey level images were captured for each fluorochrome using a Photometrics charge-coupled device (CCD) camera and chromosomes were identi®ed from DAPI banding patterns. The axis was assigned for each chromosome within a well spread metaphase, and individual FITC and rhodamine pro®les along the length of the axis were calculated. These were used to calculate the¯uorescence ratio pro®le (FITC : rhodamine) for each chromosome using software from the Digital Scienti®c SmartCapture image analysis system. Final analysis and preparation of ®gures was performed using Vysis Quips software. Final ratio pro®les were prepared from mean values of at least ®ve chromosome homologues from separate metaphase spreads.
Controls
A number of reactions were performed to control for the quality of the CGH experiments. Each CGH experiment included a slide hybridised with equal quantities of normal control DNA labelled separately with FITC and rhodamine. This was used to set the¯uorescence ratio thresholds later applied to the analysis of test DNA. Only dierences in¯uorescence ratio which fell outside the¯uctuations seen in the normal control hybridisation were taken as evidence for loss or gain of regions from the tumour material (see results).
The speci®city of the probes prepared by DOP-PCR from the control and test DNA was also analysed during the CGH experiments. Since both the test and control probes were prepared from female tissue (breast tumours and placental tissue) and the probes were hybridised to normal male chromosomes, no hybridisation to the Y chromosome was expected.
The validity of the CGH data obtained in this study was tested using a tumour sample from case 6216. After initial CGH results had been obtained, tumour cells were redissected and DNA was prepared afresh from a second sequential section taken from this case. This was then used in another set of CGH experiments and the results were compared with those obtained previously (Figure 1 ).
